Cargando…
Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study
BACKGROUND/AIMS: Tegoprazan, a new, fast, and strong potassium-competitive acid blocker, has been approved for the treatment of gastric acid-related diseases in Korea. However, real-world clinical data regarding this drug are scarce. We aimed to compare the Helicobacter pylori eradication rates of t...
Autores principales: | Jung, Yoon Suk, Kim, Sunyong, Kim, Hyun-Young, Noh, Seung Jae, Park, Jung Ho, Sohn, Chong Il, Park, Chan Hyuk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of Gut and Liver
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502490/ https://www.ncbi.nlm.nih.gov/pubmed/36510776 http://dx.doi.org/10.5009/gnl220218 |
Ejemplares similares
-
Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
por: Park, Chan Hyuk, et al.
Publicado: (2022) -
Role of Tegoprazan in Helicobacter pylori Eradication Therapy
por: Lee, Jin
Publicado: (2022) -
Comparative Efficacy of Tegoprazan vs Esomeprazole/Sodium Bicarbonate for the Treatment of Helicobacter pylori Infection
por: Park, Chan Hyuk, et al.
Publicado: (2023) -
Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication
por: Kwon, Yong Hwan, et al.
Publicado: (2023) -
Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori
por: Wu, Meng-Chieh, et al.
Publicado: (2017)